Bristol-Myers Squibb Company (BMY)
6 of Wall Street's Favorite High-Yield Blue Chip Dividend Stocks to Buy in June
24/7 Insights Quality dividend stocks can generate solid total returns and yield passive income.
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade
Pfizer stock has been beaten down so far that it offers a dividend yield above 6% at recent prices. Bristol Myers Squibb has been trading for the low multiple of about 7 times trailing free cash flow.
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
3 High-Yield Dividend Stocks for Income Now and Growth Later
The latest readings on inflation show some cooling, and stocks seem to like it. However, it's important to be clear about why investors feel bullish.
Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least
Bristol-Myers Squibb Company stock has taken a big tumble in the past quarter following its sharply reduced earnings guidance, but there are still plenty of positives going for it. Better than expected revenue growth in Q1 2024, earnings reduction being restricted to one year only and its recent cost reduction initiatives indicate better times from 2025 onwards. Its still elevated forward P/E indicates it's unlikely to see an uptick anytime this year, but it's still a good time to start buying the stock for next year.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Dividend Harvesting Portfolio Week 171: $17,100 Allocated, $1,524.12 In Projected Dividends
The markets had a strong week, with the S&P 500 gaining 0.97% and the Dow Jones Industrial Average gaining 1.6%. Yields on the 10-year Treasury shot up to 4.9% ahead of the FOMC meeting. The Dividend Harvesting Portfolio traded sideways but continues to generate consistent dividend income and exceed invested capital.
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
Key scientific achievement advances the joint pipeline in the strategic neuroscience partnership with Bristol Myers Squibb and earns a payment of US$ 20 m to Evotec to progress further research HAMBURG, GERMANY / ACCESSWIRE / June 12, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company has reached important scientific progress within its neuroscience collaboration with Bristol Myers Squibb (NYSE:BMY) triggering a research payment of US$ 20 m to Evotec. A target-based programme progresses into late pre-clinical development, further contributing to the fast-growing and promising pipeline of discovery to clinical-stage programmes in neurodegeneration that the partnership has generated.
Bristol Myers Squibb (BMY) Beats Stock Market Upswing: What Investors Need to Know
Bristol Myers Squibb (BMY) reachead $43.02 at the closing of the latest trading day, reflecting a +1.06% change compared to its last close.
Bristol-Myers Squibb Company (BMY) Goldman Sachs 45th Annual Global Healthcare Conference
Bristol-Myers Squibb Company (NYSE:BMY ) Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 11:20 AM ET Company Participants Chris Boerner - Board Chair and Chief Executive Officer Conference Call Participants Chris Shibutani - Goldman Sachs Good morning, still, I think, everybody, and welcome. We are very pleased that you're joining us here on the Second Day of the Goldman Sachs Healthcare Conference.
Why Bristol Myers Squibb Is A Top Socially Responsible Dividend Stock
Bristol Myers Squibb has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.8% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. Environmental criteria include considerations like the environmental impact of the company's products and services, as well as the company's efficiency in terms of its use of energy and resources.
7 Stocks Warren Buffett Has Sold in the Past Year (and You Should Too)
The Oracle of Omaha is by far the most well-known long-term investor we have alive today, and if you are a newbie, looking into Warren Buffett stocks to sell is a good way to weed out the bad stocks from your portfolio. I believe Berkshire Hathaway (NYSE: BRK-A , NYSE: BRK-B ) alone makes for a pretty good starter portfolio, as it acts like an exchange-traded fund with solid growth.
